Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS309403 是有效的、选择性脂肪细胞脂肪酸结合蛋白 aFABP 抑制剂。它可改善载脂蛋白 E 缺乏症小鼠和培养的人内皮细胞的内皮功能。它能够与蛋白质内部的脂肪酸结合口袋相互作用,竞争性地抑制内源性脂肪酸的结合。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 355 | 现货 | ||
5 mg | ¥ 565 | 现货 | ||
10 mg | ¥ 989 | 现货 | ||
25 mg | ¥ 2,160 | 现货 | ||
50 mg | ¥ 3,050 | 现货 | ||
100 mg | ¥ 4,270 | 现货 | ||
500 mg | ¥ 9,230 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 565 | 现货 |
产品描述 | BMS-309403 is an effective, selective and cell-permeable inhibitor of fatty acid binding protein 4 (FABP4) with a Ki of less than 2 nM. |
靶点活性 | FABP3: 250 nM , FABP4:< 2 nM, FABP5: 350 nM |
体外活性 | BMS-309403 binds to FABP4 with high affinity and shows over 100-fold selectivity against FABP5 as well as the heart isoform FABP3[1]. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner[2]. BMS-309403 stimulates glucose uptake in C2C12 myotubes in a temporal and dose dependent manner via activation of AMP-activated protein kinase (AMPK) signaling pathway but independent of FABPs[3]. |
体内活性 | A 6 week treatment with BMS-309403 improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but does not affect endothelium-independent relaxations. In cultured human microvascular endothelial cells, lipid-induced A-FABP expression is associated with reduced phosphorylated eNOS and NO production and is reversed by BMS-309403[4]. The extent of atherosclerotic lesion area in the proximal aorta is significantly reduced in the BMS-309403-treated group compared with vehicle-treated controls in both the early and late intervention studies[2]. |
分子量 | 474.55 |
分子式 | C31H26N2O3 |
CAS No. | 300657-03-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mM, Heating is recommended.
DMSO: 50 mg/mL (105.36 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1073 mL | 10.5363 mL | 21.0726 mL | 52.6815 mL |
5 mM | 0.4215 mL | 2.1073 mL | 4.2145 mL | 10.5363 mL | |
10 mM | 0.2107 mL | 1.0536 mL | 2.1073 mL | 5.2681 mL | |
20 mM | 0.1054 mL | 0.5268 mL | 1.0536 mL | 2.6341 mL | |
DMSO | 50 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 1.0536 mL |
100 mM | 0.0211 mL | 0.1054 mL | 0.2107 mL | 0.5268 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-309403 300657-03-8 Metabolism FABP Inhibitor selective oral Fatty acid-binding protein inhibit BMS 309403 endothelial uptake glucose BMS309403 function inhibitor